Yue Xiaoqiao, Bai Chenjun, Xie Dafei, Ma Teng, Zhou Ping-Kun
School of Public Health, University of South China, Hengyang, China.
Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing, China.
Front Genet. 2020 Dec 23;11:607428. doi: 10.3389/fgene.2020.607428. eCollection 2020.
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a member of the phosphatidylinositol 3-kinase related kinase family, which can phosphorylate more than 700 substrates. As the core enzyme, DNA-PKcs forms the active DNA-PK holoenzyme with the Ku80/Ku70 heterodimer to play crucial roles in cellular DNA damage response (DDR). Once DNA double strand breaks (DSBs) occur in the cells, DNA-PKcs is promptly recruited into damage sites and activated. DNA-PKcs is auto-phosphorylated and phosphorylated by Ataxia-Telangiectasia Mutated at multiple sites, and phosphorylates other targets, participating in a series of DDR and repair processes, which determine the cells' fates: DSBs NHEJ repair and pathway choice, replication stress response, cell cycle checkpoints, telomeres length maintenance, senescence, autophagy, etc. Due to the special and multi-faceted roles of DNA-PKcs in the cellular responses to DNA damage, it is important to precisely regulate the formation and dynamic of its functional complex and activities for guarding genomic stability. On the other hand, targeting DNA-PKcs has been considered as a promising strategy of exploring novel radiosensitizers and killing agents of cancer cells. Combining DNA-PKcs inhibitors with radiotherapy can effectively enhance the efficacy of radiotherapy, offering more possibilities for cancer therapy.
DNA依赖性蛋白激酶催化亚基(DNA-PKcs)是磷脂酰肌醇3激酶相关激酶家族的成员,可磷酸化700多种底物。作为核心酶,DNA-PKcs与Ku80/Ku70异二聚体形成活性DNA-PK全酶,在细胞DNA损伤反应(DDR)中起关键作用。一旦细胞中发生DNA双链断裂(DSB),DNA-PKcs会迅速被招募到损伤部位并被激活。DNA-PKcs在多个位点被自身磷酸化以及被共济失调毛细血管扩张突变蛋白磷酸化,并磷酸化其他靶点,参与一系列DDR和修复过程,这些过程决定细胞的命运:DSB非同源末端连接修复和途径选择、复制应激反应、细胞周期检查点、端粒长度维持、衰老、自噬等。由于DNA-PKcs在细胞对DNA损伤的反应中具有特殊且多方面的作用,精确调节其功能复合物的形成、动态变化及活性对于维护基因组稳定性至关重要。另一方面,靶向DNA-PKcs被认为是探索新型放射增敏剂和癌细胞杀伤剂的一种有前景的策略。将DNA-PKcs抑制剂与放疗相结合可有效提高放疗疗效,为癌症治疗提供更多可能性。